Day One Biopharmaceuticals (NASDAQ:DAWN) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a $40.00 price target on the stock.

DAWN has been the subject of a number of other research reports. JPMorgan Chase & Co. reduced their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. Finally, Needham & Company LLC lifted their price target on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Trading Down 0.9 %

Shares of NASDAQ:DAWN traded down $0.13 during midday trading on Thursday, hitting $14.59. 401,067 shares of the stock were exchanged, compared to its average volume of 933,404. The company has a 50 day moving average price of $14.18 and a 200-day moving average price of $14.39. The stock has a market cap of $1.28 billion, a P/E ratio of -14.29 and a beta of -1.51. Day One Biopharmaceuticals has a twelve month low of $10.90 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the previous year, the company earned ($0.54) earnings per share. On average, equities research analysts expect that Day One Biopharmaceuticals will post -1.65 earnings per share for the current year.

Insider Activity

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the sale, the insider now owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the sale, the general counsel now owns 26,928 shares of the company’s stock, valued at approximately $376,992. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,748 shares of company stock valued at $689,072. 8.40% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently modified their holdings of DAWN. ProShare Advisors LLC boosted its holdings in shares of Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after acquiring an additional 1,447 shares during the last quarter. Summit Rock Advisors LP purchased a new stake in Day One Biopharmaceuticals in the first quarter worth about $851,000. Altitude Crest Partners Inc. bought a new stake in Day One Biopharmaceuticals during the first quarter valued at about $3,230,000. Estuary Capital Management LP grew its stake in Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after buying an additional 728,240 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in shares of Day One Biopharmaceuticals in the first quarter worth about $221,000. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.